← Leaderboards
Laura M Hales
Extend Biosciences, Inc.
$11,058,957
Attributed
$11,281,531
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,481,915 · 4
FDA$1,799,616 · 1
By mechanism
R44$8,730,029 · 2
R01$1,799,616 · 1
R43$751,886 · 2
Top collaborators
- Alexey Wolfson2 shared
Others in their field
Top investigators on “Half-Life”
- David Heimbrook · Leidos Biomedical Research, Inc.$44,594,272
- Merit E Cudkowicz · Massachusetts General Hospital$39,269,365
- Xinhua Li · Nano Terra, Inc.$30,331,442
- James E Crowe · Vanderbilt University Medical Center$23,531,089
- Chang-Guo Zhan · University Of Kentucky$22,890,936
- Matthew W Kalnik · Antidote Therapeutics, Inc.$21,780,207
Research focus
Half-LifeRattusDoseDrug KineticsPlayPeptidesBiological AvailabilityQuality Of LifeDesignSafetyGrantDeteriorationConventional TherapyContinuous InfusionClinical TrialsFeelingHormonesChronic DiseaseHeart RhythmHormone DeficiencyCalcificationClinically SignificantBone TurnoverCalcium
Grant awards (11)
Long-acting PTH for hypoparathyroidism$999,615
R44 · FY2025 · DK · contact PI
A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022)$899,808
R01 · FY2025 · FD · contact PI
Long-acting PTH for hypoparathyroidism$999,615
R44 · FY2024 · DK · contact PI
A Phase 2 Study Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults with Hypoparathyroidism (IND146180; October 14, 2022)$899,808
R01 · FY2023 · FD · contact PI
Long-acting PTH for hypoparathyroidism$2,000,000
R44 · FY2021 · DK · contact PI
Long-acting PTH for hypoparathyroidism$1,000,000
R44 · FY2020 · DK · contact PI
Long-acting PTH for hypoparathyroidism$1,928,001
R44 · FY2018 · DK · contact PI
Long-acting PTH for hypoparathyroidism$1,802,798
R44 · FY2017 · DK · contact PI
Long acting PTH for hypoparathyroidism$306,738
R43 · FY2015 · DK · contact PI
A Systemically Deliverable RNAi-based Approach for Alcoholic Liver Disease$145,500
R43 · FY2014 · AA · contact PI
A Systemically Deliverable RNAi-based Approach for Alcoholic Liver Disease$299,648
R43 · FY2013 · AA · contact PI